Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 570910, 5 pages
http://dx.doi.org/10.1155/2014/570910
Research Article

Effect of Experimentally Induced Hepatic and Renal Failure on the Pharmacokinetics of Topiramate in Rats

1Department of Pharmacology and Therapeutics, Faculty of Pharmacy, Kuwait University, P.O. Box 24923, Safat 13110, Kuwait
2Department of Physiology and Pharmacology, School of Medicine, Al-Quds University, Abu Dees, West Bank, Jerusalem, Palestine

Received 23 August 2013; Revised 7 April 2014; Accepted 24 May 2014; Published 9 June 2014

Academic Editor: Manjari Tripathi

Copyright © 2014 Kamal M. Matar and Yasin I. Tayem. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Kaminska, “New antiepileptic drugs in childhood epilepsies: indications and limits,” Epileptic Disorders, vol. 3, no. 2, pp. 37–46, 2001. View at Google Scholar · View at Scopus
  2. R. Gursahani and N. Gupta, “The adolescent or adult with generalized tonic-clonic seizures,” Annals of Indian Academy of Neurology, vol. 15, no. 2, pp. 81–88, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. Y. Liang, X. Chen, M. Osborne, S. O. DeCarlo, T. L. Jetton, and K. Demarest, “Topiramate ameliorates hyperglycaemia and improves glucose-stimulated insulin release in ZDF rats and db/db mice,” Diabetes, Obesity and Metabolism, vol. 7, no. 4, pp. 360–369, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. A. A. Kholin, N. N. Zavadenko, E. S. Il'Ina et al., “Efficacy and safety of topiramate depending on patient's age and forms of epilepsy,” Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova, vol. 113, no. 4, pp. 45–51, 2013. View at Google Scholar · View at Scopus
  5. P. N. Patsalos, “Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies,” Epilepsia, vol. 46, no. 9, supplement, pp. 140–148, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. R. C. Sachdeo, “Topiramate: clinical profile in epilepsy,” Clinical Pharmacokinetics, vol. 34, no. 5, pp. 335–346, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. G. W. Caldwell, W. N. Wu, J. A. Masucci et al., “Metabolism and excretion of the antiepileptic/antimigraine drug, topiramate in animals and humans,” European Journal of Drug Metabolism and Pharmacokinetics, vol. 30, no. 3, pp. 151–164, 2005. View at Google Scholar · View at Scopus
  8. V. Rodighiero, “Effects of liver disease on pharmacokinetics. An update,” Clinical Pharmacokinetics, vol. 37, no. 5, pp. 399–431, 1999. View at Google Scholar · View at Scopus
  9. J. Brockmöller, T. Thomsen, M. Wittstock, R. Coupez, H. Lochs, and I. Roots, “Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests,” Clinical Pharmacology and Therapeutics, vol. 77, no. 6, pp. 529–541, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. R. M. Craig, P. Murphy, T. P. Gibson et al., “Kinetic analysis of D-xylose absorption in normal subjects and in patients with chronic renal failure,” Journal of Laboratory and Clinical Medicine, vol. 101, no. 3, pp. 496–506, 1983. View at Google Scholar · View at Scopus
  11. E. E. Ohnhaus, S. Vozeh, and E. Nuesch, “Absolute bioavailability of digoxin in chronic renal failure,” Clinical Nephrology, vol. 11, no. 6, pp. 302–306, 1979. View at Google Scholar · View at Scopus
  12. W. L. St. Peter, “Improving medication safety in chronic kidney disease patients on dialysis through medication reconciliation,” Advances in Chronic Kidney Disease, vol. 17, no. 5, pp. 413–419, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Wynne, “Drug metabolism and ageing,” Journal of the British Menopause Society, vol. 11, no. 2, pp. 51–56, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. K. K. Flaharty, A. M. Grimm, and P. H. Vlasses, “Epoetin: human recombinant erythropoietin,” Clinical Pharmacy, vol. 8, no. 11, pp. 769–782, 1989. View at Google Scholar · View at Scopus
  15. K. M. Matar, “Influence of famotidine on verapamil pharmacokinetics in rats,” European Journal of Drug Metabolism and Pharmacokinetics, vol. 30, no. 3, pp. 219–222, 2005. View at Google Scholar · View at Scopus
  16. K. M. Matar, “Therapeutic drug monitoring of topiramate by liquid chromatography-tandem mass spectrometry,” Clinica Chimica Acta, vol. 411, no. 9-10, pp. 729–734, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Bosilkovska, B. Walder, M. Besson, Y. Daali, and J. Desmeules, “Analgesics in patients with hepatic impairment: pharmacology and clinical implications,” Drugs, vol. 72, no. 12, pp. 1645–1669, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. X. Li, H. T. Hassoun, R. Santora, and H. Rabb, “Organ crosstalk: the role of the kidney,” Current Opinion in Critical Care, vol. 15, no. 6, pp. 481–487, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Stefan and T. J. Feuerstein, “Novel anticonvulsant drugs,” Pharmacology and Therapeutics, vol. 113, no. 1, pp. 165–183, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Glue, W. Sulowicz, R. Colucci et al., “Single-dose pharmacokinetics of felbamate in patients with renal dysfunction,” British Journal of Clinical Pharmacology, vol. 44, no. 1, pp. 91–93, 1997. View at Google Scholar · View at Scopus
  21. R. Lal, J. Sukbuntherng, W. Luo et al., “Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study,” Clinical Therapeutics, vol. 34, no. 1, pp. 201–213, 2012. View at Publisher · View at Google Scholar · View at Scopus